Phase III Trial of Enzastaurin for NHL Patients Initiated
Phase III Trial of Enzastaurin for NHL Patients Initiated
INDIANAPOLISEli Lilly has initiated a randomized, placebo- controlled phase III trial of its experimental agent enzastaurin as maintenance therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma (NHL) who have achieved remission after first-line therapy. In early clinical studies, enzastaurin, an oral serinethreonine kinase inhibitor, showed promising activity in NHL.
Articles in this issue
Surgeons Perform Remote Robotic Animal Nephrectomy Over Public Internet: A First
High-Quality Screening Colonoscopy Priority for GI Docs
Genentech Seeks Expanded Use of Avastin in Breast Cancer
Denosumab Suppresses Bone Resorption in Breast Ca Mets
FDA Approves Priority Review of Merck's Zolinza (Vorinostat)
FDA Approves Revlimid for Myeloma Rx
Real-Time RT Planning, Delivery in the Bronx
Phase III Trial of Enzastaurin for NHL Patients Initiated
Dr. Niederhuber, New Acting Director of NCI, Confronts the Old Problem of an Ever-Declining Institute Budget
Racial Disparities in Prostate Ca Recurrence
HNPCC Pts May Reject Prophylactic Subtotal Colectomy
Improved Colonoscopy Techniques Increase Patient Comfort
New Agents Top Standard Rx in First-Line Advanced RCC
Two Cancer Bills Introduced in the US House of Representatives
Interventions Increase Chemotherapy Center Capacity
Recent Videos
Related Content
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
